CEPI – Coalition for Epidemic Preparedness Innovations [to 3 February 2018]
24 January 2018
CEPI announces new permanent board
Media release, , London – Coalition for Epidemic Preparedness Innovations
Today, CEPI, the coalition launched one year ago to finance and coordinate the development of new vaccines to prevent and contain epidemics, announces the establishment of its new permanent Board.
The Board includes global leaders who have made extraordinary contributions to protecting and improving health, and who bring a wealth of expertise to CEPI as it moves into the next phase of its development.
CEPI’s new Board will have twelve members. Eight seats will be held by independent members, while four seats have been reserved for investors. The independent members are:
:: Dr Awa Coll-Seck, Minister of State and Former Minister of Health and social welfare of the Republic of Senegal
:: Jane Halton, (Chair), former Secretary of the Australian Department of Finance
:: Professor Cherry Gagandeep Kang, Christian Medical College Vellore
:: Dr Joanne Liu, International President, MSF
:: Dr John Nkengasong, Director of the Africa Centers for Disease Control and Prevention
:: Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine
:: Dr David Reddy, CEO, Medicines for Malaria Venture
:: Dr Rajeev Venkayya, President, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited
The four investor seats will be named by CEPI’s newly formed Investors Council. It is anticipated that three seats will be held by sovereign investors and one by a philanthropic investor.
Dr Richard Hatchett, CEO of CEPI, said: “I’m delighted to welcome these eminent experts to our Board. This is a seminal moment in CEPI’s development as we invest in developing the vaccines and capabilities that the world currently lacks to prepare against future epidemics. CEPI is fortunate to have a Board of this calibre to advise us as we deliver our mission to make the world safer through new vaccines.”
Emory Vaccine Center [to 3 February 2018]
Jan. 30, 2018
2018 Japan Prize is awarded to Emory immunologist Max Cooper
By Sarah Mars Bowie | Woodruff Health Sciences Center |
The Japan Prize Foundation has announced Max D. Cooper, MD, as a laureate of the 2018 Japan Prize. Alongside Dr. Jacques Miller, Cooper is being awarded the prize in the category “Medical Science and Medicinal Science” for the discovery of the dual nature of adaptive immunity, which identified the cellular building blocks of the immune system as we understand it today.
The annual Japan Prize awards recognize individuals who are pioneers in their respective fields of medicinal science and resources, energy, environment and social infrastructure…
European Medicines Agency [to 3 February 2018]
Strengthened guidance on follow-up and risk management for ATMP developers
Guideline to streamline procedures and better address the specific requirements of ATMP developers published for consultation…
FDA [to 3 February 2018]
January 30, 2018
FDA, USDA announce formal agreement to bolster coordination and collaboration
U.S. Agriculture Secretary Sonny Perdue and FDA Commissioner Scott Gottlieb, M.D. announced at the White House today a formal agreement aimed at making the oversight of food more efficient and effective by bolstering coordination between the two agencies. The formal agreement outlines efforts to increase interagency collaboration, efficiency and effectiveness on produce safety and biotechnology activities, while providing clarity to manufacturers.
“Today, Commissioner Gottlieb and I signed a formal agreement to promote coordination and the streamlining of capacities and obligations on shared concerns and jurisdiction,” said Secretary Perdue. “Congress passed the Food Safety Modernization Act and assigned responsibilities to the USDA and the FDA. The USDA has the knowledge and expertise to support the FDA’s work related to farming. We at the USDA have a motto: Do Right, and Feed Everyone. We believe this joint effort will help us move one step closer to that goal.”…
Global Fund [to 3 February 2018]
Burkina Faso and Global Fund Launch New Grants to Accelerate Progress against HIV, TB and Malaria
01 February 2018
OUAGADOUGOU – Burkina Faso and the Global Fund strengthened their partnership by launching four new grants that move toward ending epidemics of HIV, tuberculosis, malaria and strengthen health systems with a focus on community health systems and data quality.
The new investments will support efforts to scale up HIV programs to achieve the 90-90-90 targets by enrolling more than 93,000 people on antiretroviral treatment by 2020, and expanding HIV services, including access to prevention and treatment for key populations. The new grants also aim to strengthen the country’s supply-chain management, improve TB case detection, and procure 12 million mosquito nets for the 2019 mass distribution campaign.
…The four grants, worth a total of EUR130 million for the 2018-2020 implementation period, bring the total amount of Global Fund grants allocated to Burkina Faso to EUR427 million. The grants will be managed by le Programme d’Appui au Développement Sanitaire, le Comité National de Lutte contre le Sida — and l’Initiative Privée pour la lutte contre le SIDA/IPC…
Tanzania and Global Fund Sign New Grants to Accelerate End of Epidemics
30 January 2018
The Global Fund and health partners in Tanzania yesterday signed grant agreements to work toward ending the epidemics of HIV, tuberculosis and malaria.
MSF/Médecins Sans Frontières [to 3 February 2018]
Liberia: MSF Opens Pediatric Surgery Program
MONROVIA, LIBERIA/NEW YORK, JANUARY 31, 2018—Doctors Without Borders/Médecins Sans Frontières (MSF) opened a pediatric surgical program at Bardnesville Junction Hospital (BJH) on the outskirts of Liberia’s capital Monrovia on Jan. 11, with a goal of making surgical care more available for children in the country.
Syria: Deadly Airstrikes Damage Hospital Supported by MSF in Idlib
AMMAN, JORDAN/NEW YORK, JANUARY 29, 2018—Two airstrikes hit a hospital supported by Doctors Without Borders/Médecins Sans Frontières (MSF) in Syria’s Idlib governorate today, causing deaths and injuries and seriously damaging the facility, according to the hospital manager, who contacted MSF.
Mediterranean: 99 People Rescued From Sinking Dinghy, Many Others Presumed Drowned
New York, January 28, 2018—In a nightmarish day on the Mediterranean Sea yesterday, 99 survivors from a sinking rubber boat were rescued by the Aquarius, a search and rescue vessel run by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and SOS MEDITERRANEE. An unknown number of men, women, and children are missing and presumed drowned. Two women are confirmed dead.
NIH [to 3 February 2018]
February 1, 2018
The Human Genome Project is awarded the Thai 2017 Prince Mahidol Award for the field of medicine
February 1, 2018 — The award will be received on behalf of the project by NHGRI Director Dr. Eric Green.
NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease
January 30, 2018 — Effort is part of the Accelerating Medicines Partnership to speed development of disease-altering treatments.
Roadmap to guide progress toward replacing animal use in toxicity testing
January 30, 2018 — Framework aims to provide more human relevant toxicology data.
PATH [to 3 February 2018]
Announcement | February 01, 2018
LabCorp CEO Dave King becomes PATH board chair
PATH is pleased to announce that its board of directors has confirmed David P. King as board chair. Mr. King, who is chairman and CEO of LabCorp, a leading global life sciences company, has served on the PATH board since 2013.
“As a PATH board member, Dave has applied his private-sector experience to the biggest health challenges facing our world,” said Steve Davis, PATH’s president and CEO. “He is a brilliant business leader who is deeply committed to health equity, and we are delighted that he is now our board chair.”
Mr. King succeeds Dean Allen, who recently completed a three-year term as board chair…
Press release | January 31, 2018
DRC government steps up commitment to eliminating sleeping sickness by 2020
International partners support government in innovative approach to fight devastating disease
Announcement | January 30, 2018
New research consortium to evaluate evidence for single-dose HPV vaccination
Leading health and research institutions come together to evaluate the evidence for potential single-dose HPV vaccination schedule.
The Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH and encompassing nine leading research institutions, has begun work to collate and synthesize existing evidence and evaluate new data on the potential for single-dose human papillomavirus (HPV) vaccine delivery.
While 80 countries and territories have introduced HPV vaccines on a two- or three-dose schedule into their national immunization schedules, rollout in low- and lower-middle-income countries has lagged. If demonstrated to be effective, single-dose HPV vaccination could significantly accelerate national vaccine introduction by simplifying programs and lowering procurement and delivery costs.
Funded by the Bill & Melinda Gates Foundation, the consortium will review existing evidence and evaluate new information available from trials and other observational studies on the effectiveness of a single-dose schedule in order to inform global policy discussions and guidance around HPV vaccination. A group of modeling experts within the consortium will also analyze data, identify critical data gaps, and conduct exploratory what-if scenarios to estimate the impact and cost-effectiveness of a single-dose schedule versus non-vaccination or two-dose schedules to inform decision-making.
The consortium, coordinated by PATH, includes Harvard University, the London School of Hygiene & Tropical Medicine, Université Laval, the University of British Columbia, the US Centers for Disease Control and Prevention, the US National Cancer Institute, Wits Reproductive Health and HIV Institute, and the World Health Organization.
In addition to the consortium members, representatives from the following institutions serve as advisors: the British Columbia Provincial Health Services Authority; International Agency for Research on Cancer; Medical Research Council Unit, The Gambia; Instituto Nacional de Salud Pública de Mexico; and Quebec Institut National de Santé Publique.
Announcement | January 29, 2018
PATH statement on official relations status with the World Health Organization
Executive Board votes for admission of PATH into official relations with the WHO
A statement from PATH’s Geneva Office Director Philippe Guinot follows:
“As PATH celebrates 40 years of supporting global health innovation, we welcome the approval of our official relations status with the World Health Organization. We have enjoyed a very close and productive collaborative relationship with WHO, and look forward to continuing to work side-by-side toward the advancement of public health in the future.”
UNAIDS [to 3 February 2018]
31 January 2018
African human rights body urges renewed efforts on human rights in response to HIV
On 27 January, the African Commission on Human and Peoples’ Rights (the African Commission) launched a groundbreaking report, HIV, the law and human rights in the African human rights system: key challenges and opportunities for rights-based responses.
The report addresses the key human rights challenges in the response to HIV, including inequality and discrimination towards people living with HIV, access to treatment and restrictive intellectual property regimes, conflict and migration, coercive HIV testing and counselling, restrictions on civil society and the criminalization of people living with HIV and key populations.
While noting the progress made in the response to HIV in Africa, the report expresses concerns about the populations left behind—young women and girls, prisoners, sex workers, men who have sex with men, transgender people and people who use drugs.
As well as the challenges, the report also highlights good practices from across the continent for responding to them, including law and policy reform, progressive court decisions and programmes to advance human rights protection and access to HIV and health services.
The development of the report is the result of three years of work involving inputs from various stakeholders, including people living with and affected by HIV, civil society and members of key populations.
UNICEF [to 3 February 2018]
31 January 2018
3 in 10 young people in conflict or disaster-stricken countries are illiterate – UNICEF
NEW YORK, 31 January 2018 – Nearly 3 in 10 young people aged between 15 and 24 years old – 59 million – living in countries affected by conflict or disaster are illiterate, triple the global rate, UNICEF said today.
UNICEF seeks $3.6 billion in emergency assistance for 48 million children caught up in catastrophic humanitarian crises
NEW YORK/GENEVA, 30 January 2018 – UNICEF appealed today for $3.6 billion to provide lifesaving humanitarian assistance to 48 million children living through conflict, natural disasters and other emergencies in 51 countries in 2018.
Wellcome Trust [to 3 February 2018]
News / Published: 25 January 2018
What our new strategy means for the Public Engagement Fund
We’ve developed an ambitious new strategy for our public engagement work and, as a result, we are making some changes to the Public Engagement Fund.
When we launched the Public Engagement Fund in January 2017 we said that the fund would evolve – as we learned from its implementation, and to reflect Wellcome’s changing vision.
After the changes, funding will still be open to anyone with a great project for engaging the public in Wellcome’s mission of improving health…
News / Published: 22 January 2018
New Wellcome office in Berlin will bolster global partnerships
News / Published: 22 January 2018
Wellcome is planning to open a small office in the German capital later this year so that we can work more closely with our international partners on shared priorities…
DCVMN – Developing Country Vaccine Manufacturers Network [to 3 February 2018]
17 January 2018
DCVMN and the Future Vaccine Manufacturing Hub launched a novel partnership for responsible innovation in emerging countries
[See Milestones above for more detail]
Industry Watch [to 3 February 2018]
:: Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
January 29, 2018
The Fast Track designation highlights the significance of Zika and the need for a safe and effective vaccine to protect vulnerable populations
A Phase 1 clinical trial (ZIK-101) was recently initiated to evaluate Takeda’s Zika vaccine candidate (TAK-426) in the continental U.S. and U.S. territories
Takeda’s Zika program is supported by federal funds from Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services